Business
Restoration of Trading
Restoration of Trading.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n7 June 2023\n \nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nRestoration of Trading\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, advises that following the publication of the Company's 2022 Annual Report on 5 June 2023 and an application by the Company for the suspension to be lifted, the Company's shares will be restored to the Official List and to trading on the London Stock Exchange today. \nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION EU NO. 596/2014, AS RETAINED AND APPLICABLE IN THE UK PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n-ENDS-\nEnquiries:\n\n\n\n\nRoquefort Therapeutics plc\n\n\n\n\nStephen West (Chairman) / Ajan Reginald (CEO)\n\n\n+44 (0)20 3290 9339\n \n\n\n\n\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\n \nOptiva Securities Limited (Joint Broker)\n\n\n \n+44 (0)203 764 2341\n\n\n\n\nChristian Dennis\n \nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n \n\n\n+44 (0)20 3411 1881\n \n \n+44 (0)20 7466 5000\n \n\n\n\n\n \nLEI: 254900P4SISIWOR9RH34\n \nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\n \nSince listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\n \nRoquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n· Midkine antibo...